Lactitol, a Potential Second Generation Disaccharide Drug for the Treatment of Portal-Systemic Encephalopathy
In 1966 the first report of the beneficial effects of lactulose in the treatment of chronic portal systemic encephalopathy was published.1 In the meantime, this drug has become accepted as drug of choice for this condition,2 but also some disadvantages of lactulose — available only as syrup with a very sweet taste and contamination by other sugars — have now been recognized. Unfortunately these features may lead to aversion against the drug, to nausea related to the hyperosmolarity of the syrup and consequently to suboptimal treatment. In view of these difficulties it is surprising that no analogs with more favorable physiochemical properties have as yet been investigated.
KeywordsHepatic Encephalopathy Sweet Taste Hepatic Coma Chronic Liver Failure Conjugate Bile Acid
Unable to display preview. Download preview PDF.
- 2.H. O. Conn and M. M. Lieberthal,“The hepatic coma syndromes and lactulose,” The Williams and Wilkins Co., Baltimore (1979).Google Scholar
- 4.J. Bircher, M. Bührer, K. Franz, and J. A. van Velthuijsen, Erstmalige Anwendung von Lactitol in der Behandlung der portosystemischen Encephalopathie, Schweiz. Med. Wschr. 112: 1306 (1982).Google Scholar